| Cat. No. |
Product Name |
Information |
| PC-Ab1109 |
Guselkumab
|
Guselkumab (CNTO-1959) is a fully human immunoglobulin-G1-lambda (IgG1λ) monoclonal antibody, selectively binds to the p19 subunit of IL-23 in dendritic cells and keratinocytes and blocks its interaction with the IL-23 receptor, which further prevents the release of other pro-inflammatory cytokines and chemokines via stimulation of immune cells, such as T helper 17 (Th17) cells. Guselkumab serum levels of IL-17A, IL-17F, and IL-22, inhibits the release of proinflammatory cytokines and chemokines |
| PC-Ab1108 |
Sabatolimab
|
Binds and blocks the interaction TIM3/PtdSer (Kd=0.16 nM, PtdSer Blocking IC50=6.4 nM) , restore effector T cell activity to promote antitumor immunity by altering myeloid cells in tumor microenvironment. TIM-3 may synergize with PD-1 blockade by enhancing or altering the innate immune response and may form part of a resistance mechanism to PD-1 blockade.. |
| PC-Ab1107 |
TSR-033
|
TSR-033 is a high affinity humanized IgG4, κ mAb that specifically binds LAG-3 and blocks the interaction between LAG-3 and its ligand MHC Class II. TSR-033 serves as a functional antagonist, enhancing in vitro T-cell activation both in mixed lymphocyte reactions and staphylococcal enterotoxin B-driven stimulation assays. In a humanized mouse non-small cell lung carcinoma model, TSR-033 boosted the antitumor efficacy of PD-1 monotherapy, with a concomitant increase in immune activation.. |
| PC-Ab1106 |
Rovalpituzumab
|
Rovalpituzumab is the antibody part of Rovalpituzumab tesirine (Rova-T). Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially developed for small cell lung cancer.. |
| PC-Ab1105 |
Oleclumab
|
Oleclumab (MEDI 9447) is a human IgG1 lambda mAb with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. |
| PC-Ab1104 |
Sintilimab
|
Sintilimab (IBI 308) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. . |
| PC-Ab1103 |
Toripalimab
|
Toripalimab (JS 001, SO-001, TAB-001) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function. Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells.. |
| PC-Ab1102 |
Leramilimab
|
LAG525 (Leramilimab) is a high-affinity, ligand-blocking monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth. LAG525 blocks binding of LAG-3, a negative regulator of T-cell signalling, to MHC class II on tumour cells, which renders the tumour microenvironment less immunosuppressive, and may therefore enhance the activity of PD-1 blockade.. |
| PC-Ab1101 |
Nesvacumab
|
Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand vascular growth factor called angiopoietin2 (Ang2) with high affinity (Kd=24 pM), but shows no binding to Ang1.. |
| PC-Ab1100 |
Palivizumab
|
Palivizumab (MEDI-493) is a monoclonal antibody to the RSV F protein that inhibits binding of the virus to cellular receptors. This reduces viral activity and cell-to-cell transmission, and blocks the fusion of infected cells. Palivizumab is directed at an epitope in the A antigenic site of the 'F' protein on the surface of RSV. Palivizumab binds to this epitope, which is highly conserved among different RSV isolates.. |
| PC-Ab1099 |
Dacetuzumab
|
Dacetuzumab (SGN-40, huS2C6) is a humanized anti-CD40 monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor. Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. Dacetuzumab demonstrated antitumor activity in relapsed/refractory diffuse large |
| PC-Ab1098 |
Gemtuzumab
|
Gemtuzumab is a biosimilar directed against the extracellular domain of CD33. This product constitutes the immunogen used for the anti-Idiotype catalog numbers MAB9617 and MAB96171. The biotinylated antibody (catalog number FAB9635B) can be used in flow cytometry or various assay format to measure Siglec‑3/CD33 expression and can be detected by conjugated streptavidin. Gemtuzumab is the antibody part of Gemtuzumab ozogamicin.. |
